The RadioGenix System uses reliable, domestic, non-uranium based Mo-99 to supply physicians and patients with technetium-99m (Tc-99m). The awards will also be used in continuing development of enhancements for the FDA-approved and commercially available RadioGenix® System (technetium Tc-99m generator). NorthStar will also be required to provide an equal amount of matching funds.
Both projects support non-uranium based, environmentally friendly production of Mo-99.ĭOE/NNSA will provide $16.3M in funding for the neutron capture project and $20.7M for the accelerator project. NorthStar will use funds from the award to complete its neutron capture technology programme and continue development and expansion of its accelerator production programme. US-based NorthStar Medical Radioisotopes announced on 30 August that it has been awarded $37 million in cooperative agreement funds with the US Department of Energy’s National Nuclear Security Administration (DOE/NNSA) as part of an industry outreach initiative to establish reliable domestic molybdenum-99 (Mo-99) production without the use of highly enriched uranium (HEU).
0 kommentar(er)
